Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and Innovation [Yahoo! Finance]
Inhibrx Biosciences, Inc. (INBX)
Company Research
Source: Yahoo! Finance
programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma ("I-Mab") in the United States District Court for the District of Delaware . The jury found in favor of Inhibrx, rejecting all allegations of misappropriation before it, confirming the Company's adherence to high ethical standards and innovation in scientific research. I-Mab had initiated the lawsuit on March 1, 2022 , alleging that Inhibrx and its Chief Scientific Officer, Brendan Eckelman , Ph.D., improperly accessed and used proprietary information related to several of I-Mab's research projects during a prior arbitration proceeding involving I-Mab, for which Dr. Eckelman served as an expert witness. However, the jury found absolutely no basis for these claims, validating Inhibrx's independent development processes and principled conduct in advancing its therapeutic innovations. "Inhibrx was founded on the values
Show less
Read more
Impact Snapshot
Event Time:
INBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
INBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
INBX alerts
High impacting Inhibrx Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
INBX
News
- The recent drop in prices must have disappointed Inhibrx Biosciences, Inc. (NASDAQ:INBX) institutional investors who own 43% of the shares [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences Reports Third Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- Inhibrx Biosciences Reports Third Quarter 2024 Financial ResultsPR Newswire
- Inhibrx Prevails in Trade Secret Case, Reaffirming Its Commitment to Integrity and InnovationPR Newswire
- Inhibrx: The Biotech Spinoff Poised For Big Gains [Forbes]Forbes
INBX
Earnings
- 2/28/24 - Miss
INBX
Sec Filings
- 11/14/24 - Form SC
- 11/14/24 - Form SC
- 11/14/24 - Form 424B3
- INBX's page on the SEC website